There was a smattering of new information, primarily about ADXS-HOT; the (interim) CEO said ADXS will submit two INDs related to ADXS-HOT in 2018, each for a distinct cancer type, and that ADXS has already manufactured 10 distinct instantiations of HOT (i.e. 8 of these are for potential indications other than the two designated for an IND submission in 2018).
The old CEO was burning cash at much too fast a pace and he was somewhat of a con man, IMO; however, it’s too soon to say whether cash burn will be materially reduced under the new (interim) CEO.
A related question: Why is ADXS not seeking to hire a permanent CEO (#msg-135546461)?
I wouldn’t bank on regulatory approval for PETX (ADXS’ licensee for AT-014) being much of a driver for ADXS’ share price.
Of course, but ADXS hasn’t done much right lately. Almost every clinical and regulatory milestone for 2H17 has been missed, and the long delay in starting the ADXS-NEO phase-1 (#msg-134670005) is especially hard to fathom.
All told, I think ADXS is a pretty shaky company, but the low enterprise value, the intriguing Lm platform, and the apparent confidence of AMGN justify holding a modest position. I recently added shares at $3.18 (#msg-136019282).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.